§ 5.107 - Extensions or stays of effective dates for compliance with certain labeling requirements for human prescription drugs.  


Latest version.
  • (a) The following officials are authorized to extend or stay an effective date in § 201.59 of this chapter for compliance with certain labeling requirements for human prescription drugs.

    (1) For drugs assigned to their organizations:

    (i) The Director and Deputy Directors, Center for Biologics Evaluation and Research (CBER).

    (ii) The Directors and Deputy Directors, Office of Blood Research and Review (OBRR), Office of Vaccines Research and Review (OVRR), and Office of Therapeutics Research and Review (OTRR), CBER.

    (iii) The Directors and Deputy Directors of the Divisions in OBRR, OVRR, and OTRR, CBER.

    (2) For drugs assigned to their organizations:

    (i) The Director, the Deputy Director, and the Directors, Office of Review Management and Office of Pharmaceutical Science, Center for Drug Evaluation and Research (CDER).

    (ii) The Directors and Deputy Directors of the Offices of Drug Evaluation I, II, III, IV, and V, Office of Review Management, CDER.

    (iii) The Directors and Deputy Directors of the divisions in the Offices of Drug Evaluation I, II, III, IV, and V, Office of Review Management, CDER.

    (b) These officials may not further redelegate this authority.